Affimed NV
NASDAQ:AFMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Azucar Minerals Ltd
OTC:AXDDF
|
CA |
Affimed NV
Gross Profit
Affimed NV
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Affimed NV
NASDAQ:AFMD
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Gross Profit
€2.4B
|
CAGR 3-Years
-45%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Gross Profit
€429.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunic Inc
NASDAQ:IMUX
|
Gross Profit
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Gross Profit
€147.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-4%
|
|
Affimed NV
Glance View
Affimed NV engages in the discovery and development of cancer immunotherapies. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 187 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
